Zydus obtains FDA OK for 2 generics

Zydus has received the Food and Drug Administration’s permission for two generics.

The FDA approved the company's dexamethasone tablets 1 mg.

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders. 

The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh.

Zydus launches generic Myrbetriq

Dexamethasone tablets, 1 mg had a market value of $1.8 million, per IQVIA March 2024 data.

Zydus also received the green light from the FDA for generic Dapsone Gel, 7.5%, Zydus Lifesciences said in a regulatory filing.

Dapsone Gel is used to treat acne.

It will be manufactured at the group's topical manufacturing facility in Changodar, Ahmedaba.

[Read more: Zydus obtains FDA nod for generic Sabril]